Raymond James Financial Inc Corvus Pharmaceuticals, Inc. Transaction History
Raymond James Financial Inc
- $264 Billion
- Q4 2024
A detailed history of Raymond James Financial Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 108,989 shares of CRVS stock, worth $585,270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
108,989Holding current value
$585,270% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
76Shares Held
30.5MCall Options Held
1.06MPut Options Held
84.3K-
Orbimed Advisors LLC San Diego, CA6.94MShares$37.3 Million0.86% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$29.9 Million0.08% of portfolio
-
Samlyn Capital, LLC New York, NY4.53MShares$24.3 Million0.39% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$17.6 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$13 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $250M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...